METHODS: Data from the 2011-2013 US National Health and Wellness Survey, a nationally representative, self-administered, internet-based survey of adults (≥18 years old), were used to identify allergic asthma patients currently on ICS and LABA combination therapy (N=1,923). Allergic asthma was defined by a self-reported physician diagnosis of asthma and at least one of the following allergic comorbid conditions: chronic hives, nasal allergies, hay fever, atopic dermatitis, dermatitis, eczema, or skin allergies. Patients were grouped by asthma control using their scores on the Asthma Control Test (ACT; scores ≤15: very poorly controlled, 16-19: not well-controlled and 20-25: well-controlled asthma). HRQoL was assessed with the physical component summary score (PCS), mental component summary score (MCS), and SF-6D health utilities derived from the SF-12v2 and SF-36v2. Generalized linear models, controlling for covariates (i.e., demographics and health characteristics), examined whether HRQoL differed by asthma control. Adjusted means and p-values were reported from these models.